Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 17/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15911360 | 1.00 | RIPK1 (0.55) | RIPK1CTSLCTSK | |
| SCHEMBL1978907 | 0.96 | RIPK1 (0.56) | RIPK1 | |
| SCHEMBL1979174 | 0.93 | RIPK1 (0.49) | RIPK1 | |
| SCHEMBL15911572 | 0.93 | RIPK1 (0.49) | RIPK1 | |
| SCHEMBL1975566 | 0.90 | RIPK1 (0.52) | RIPK1 | |
| SCHEMBL15911546 | 0.89 | RIPK1 (0.49) | RIPK1 | |
| SCHEMBL12589524 | 0.89 | RIPK1 (0.49) | RIPK1 | |
| SCHEMBL1975159 | 0.89 | RIPK1 (0.51) | RIPK1 | |
| SCHEMBL1978818 | 0.89 | RIPK1 (0.51) | RIPK1 | |
| SCHEMBL12589927 | 0.89 | RIPK1 (0.51) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8716263-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2014-05-06 | — | — | US | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT1, DGAT2, LCAT | RIPK1 3703/4885CTSL 4528/4885CTSK 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.